KBC Group
IRON icon

KBC Group’s Disc Medicine IRON Stock Holding History

KBC Group’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74K Hold
1,011
– – ﹤0.01% 1568
2026
Q1 		$65K Hold
1,011
– – ﹤0.01% 1552
2025
Q4 		$80K Buy
+1,011
New +$85.4K ﹤0.01% 1427

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KBC Group's IRON Position: Q2 2026 in Review

KBC Group held its Disc Medicine (IRON) position steady in Q2 2026 at 1,011 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

KBC Group first reported a position in IRON in Q4 2025 and has held it in 3 quarters since. The position peaked at $80K in Q4 2025. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • KBC Group held 1,011 shares of Disc Medicine worth $74K as of Q2 2026.
  • KBC Group left its Disc Medicine share count unchanged in Q2 2026.
  • Disc Medicine made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1568 holding.
  • KBC Group first reported a position in Disc Medicine in Q4 2025 and has held it in 3 quarters since.
  • KBC Group's Disc Medicine position peaked at $80K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.